Market niche Clinical stage in-vitro diagnostics focused on rapid, in-office differentiation of bacterial versus viral rhinosinusitis presents a clear sales angle to primary care and ENT clinics seeking point-of-care solutions that can reduce unnecessary antibiotics and improve patient management.

Key target Primary care physicians and otolaryngologists are the primary customers, suggesting a direct sales approach through clinic partnerships, with emphasis on in-office workflow compatibility and quick patient throughput benefits.

Competitive edge First-of-its-kind rapid diagnostic kit enables definitive bacterial sinusitis diagnosis at the point of care, positioning the company against broad reference labs and traditional antibiotic prescribing, appealing to clinics aiming to optimize antibiotic stewardship and care quality.

Growth ramp Small team with early funding and a scalable digital-enabled product stack indicates potential for rapid pilots and regional expansions, leveraging cost-effective cloud-based deployment and existing healthcare tech integrations.

Strategic partnerships Opportunity to partner with large, data-driven labs and diagnostics groups as potential distributors or co-development partners, given similarities to larger peers and the desire to differentiate with rapid, at-point-of-care testing.